Advertisement

Drugs

, Volume 69, Issue 15, pp 2035–2043 | Cite as

Newer Biological Agents in the Treatment of Rheumatoid Arthritis

Do the Benefits Outweigh the Risks?
  • Michael T. NurmohamedEmail author
Leading Article

Abstract

Recently, three new biological agents, rituximab, abatacept and tocilizumab, have become available for the treatment of rheumatoid arthritis (RA) in patients with active disease, who have not responded to at least one disease-modifying antirheumatic drug (DMARD). Rituximab is an anti-CD20 monoclonal antibody, abatacept modulates T-cell activation and tocilizumab is an interleukin-6 receptor antagonist. Clinical studies with these agents have demonstrated that they are effective in RA patients with moderate to active disease, who have not responded to treatment with at least one DMARD and/or tumour necrosis factor (TNF) inhibitor. Thus far, there is no convincing evidence to show that one of these three new drugs has a superior efficacy over the others or that they have other benefits compared with the TNF inhibitors. The use of rituximab, instead of another TNF inhibitor, might be an option in patients who have not responded to TNF blockade. Abatacept could also be considered, but this has not yet been formally tested. A practical advantage of tocilizumab is that it may be administered as a first-line biological agent.

Adverse events, including (usually mild) infusion reactions, are common. There is a small increased risk of serious infections that appears to be similar to that with TNF inhibitors, although each drug may have its own particular risk profile. Thus far, there is no convincing evidence that the new biological agents are associated with an increased risk of malignancies. However, the number of patient-years studied is still rather limited and, hence, continuous postmarketing surveillance is necessary. Adequate studies directly comparing new biological agents with each other and with other biological agents, such as TNF inhibitors, are not available. Hence, no firm conclusions regarding the benefit-risk profile of these agents versus each other can be reached. However, the benefit for a given new biological agent currently appears to outweigh the risk for an individual RA patient with active disease, despite earlier drug treatment.

Keywords

Rheumatoid Arthritis Infliximab Rheumatoid Arthritis Patient Tocilizumab Abatacept 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006 Dec; 36(3): 182–8PubMedCrossRefGoogle Scholar
  2. 2.
    Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005 Nov; 64 Suppl. 4: iv2–14PubMedCrossRefGoogle Scholar
  3. 3.
    Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009 Jun; 36(6): 1118–25PubMedCrossRefGoogle Scholar
  4. 4.
    Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007 Dec 1; 370(9602): 1861–74PubMedCrossRefGoogle Scholar
  5. 5.
    Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140–74PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 Jun 17; 350(25): 2572–81PubMedCrossRefGoogle Scholar
  7. 7.
    Felson DT, Anderson JJ, Boers M, et al.,American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38(6): 727–35PubMedCrossRefGoogle Scholar
  8. 8.
    Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 Jan; 38(1): 44–8PubMedCrossRefGoogle Scholar
  9. 9.
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 May; 54(5): 1390–400PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54(9): 2793–806PubMedCrossRefGoogle Scholar
  11. 11.
    Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009 Feb; 68(2): 216–21PubMedCrossRefGoogle Scholar
  12. 12.
    Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative antitumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007 May; 56(5): 1417–23PubMedCrossRefGoogle Scholar
  13. 13.
    Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007 Dec; 56(12): 3896–908PubMedCrossRefGoogle Scholar
  14. 14.
    Thurlings RM, Vos K, Gerlag DM, et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008 Dec; 58(12): 3657–64PubMedCrossRefGoogle Scholar
  15. 15.
    Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009 Feb; 38(4): 265–80PubMedCrossRefGoogle Scholar
  16. 16.
    Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 2009; 113(20): 4834–40PubMedCrossRefGoogle Scholar
  17. 17.
    US Food and Drug Administration. MedWatch 2008 safety alerts for human medical products [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094994.htm [Accessed 2009 Aug 1]
  18. 18.
    Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007 Feb; 66(2): 143–50PubMedCrossRefGoogle Scholar
  19. 19.
    Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 Sep 15; 353(11): 1114–23PubMedCrossRefGoogle Scholar
  20. 20.
    Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008 Apr; 67(4): 547–54PubMedCrossRefGoogle Scholar
  21. 21.
    Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006 Jun 20; 144(12): 865–76PubMedGoogle Scholar
  22. 22.
    Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008 Aug; 67(8): 1084–9PubMedCrossRefGoogle Scholar
  23. 23.
    Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008 Aug; 67(8): 1096–103PubMedCrossRefGoogle Scholar
  24. 24.
    European Medicines Agency. EPARs for authorised medicinal products for human use: Orencia [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/orencia/orencia.htm [Accessed 2009 Mar 12]
  25. 25.
    Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008 Mar 22; 371(9617): 987–97PubMedCrossRefGoogle Scholar
  26. 26.
    Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19(1): 12–9PubMedCrossRefGoogle Scholar
  27. 27.
    Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008 Oct; 58(10): 2968–80PubMedCrossRefGoogle Scholar
  28. 28.
    Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multi-centre randomised placebo-controlled trial. Ann Rheum Dis 2008 Nov; 67(11): 1516–23PubMedCrossRefGoogle Scholar
  29. 29.
    Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009 Oct; 68(10): 1580–4PubMedCrossRefGoogle Scholar
  30. 30.
    Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007 Sep; 66(9): 1162–7PubMedCrossRefGoogle Scholar
  31. 31.
    European Medicines Agency. EPARs for authorised medicinal products for human use: RoActemra [online]. Available from: URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/RoActemra/RoActemra.htm [Accessed 2009 Mar 12]
  32. 32.
    Venkateshan SP, Sidhu S, Malhotra S, et al. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology 2009; 83(1): 1–9Google Scholar
  33. 33.
    Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009 Jan; 68(1): 25–32PubMedCrossRefGoogle Scholar
  34. 34.
    Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. Epub 2008 Dec 29Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of RheumatologyVU University Medical CentreAmsterdamthe Netherlands
  2. 2.Jan van Breemen InstituteAmsterdamthe Netherlands

Personalised recommendations